

Amendments to the Claims

Listing of Claims:

Claim 1 (currently amended): A combination which comprises (a) a vasculostatic compound which is PTK787 or a pharmaceutically acceptable salt thereof and (b) an alkylating agent in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt for simultaneous, separate or sequential use.

Claim 2 (original): A combination according to claim 1 wherein the alkylating agent is selected from the group consisting of alkyl sulfonates, aziridines, epoxides, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, imidazotetrazinones, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman and procarbazine.

Claim 3 (cancelled)

Claim 4 (original): A combination according to claim 1 wherein the vasculostatic compound is PTK787 or a salt thereof and the alkylating agent is temozolomide or lomustine.

Claim 5 (cancelled)

Claim 6 (cancelled):

Claim 7 (previously presented): A method of treating a warm-blooded animal having a tumor disease which comprises administering to the animal a combination according to claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 8 (previously presented): A method of inhibiting the formation of metastases in a warm-blooded animal having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 9 (original): A method according to claim 7 wherein the tumor disease is glioblastoma.

Claim 10 (cancelled)

Claim 11 (currently amended): A method according to claim ~~40~~8 wherein PTK787 is administered in a daily dose between 250 and 2000 mg.

Claim 12 (previous;y presented): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.

Claim 13 (cancelled).